Skip to main content
. 2020 Aug 7;14:136. doi: 10.3389/fnbeh.2020.00136

Figure 1.

Figure 1

Behavioral analyses and miRNA levels after CMS exposure and fluoxetine treatment. (A) CMS protocol was applied for 6 weeks and fluoxetine treatment was performed during the last 2 weeks. Behavioral analyses and blood collection were performed at the end of the CMS protocol. (B) Novelty suppressed feeding (NSF) test was applied to evaluate anxiety-like behavior; left panel: latency to feed and right panel: appetite drive. (C) Sweet Drive Test (SDT) was used to assess anhedonia. (D) Corticosterone levels measured in the blood serum of rats between 8:00 and 9:00 (basal levels, Nadir, N) and between 20:00 and 21:00 (peak levels, Zenith, Z). (E) Relative levels of miRNA-409-5p in the dorsal (dDG) and ventral dentate gyrus (vDG), CA regions of the hippocampus (HPC), prefrontal cortex (PFC), nucleus accumbens (NAc), and in the blood. (F) Relative levels of miR-411-5p in the dDG, vDG, HPC, PFC, NAc, and in the blood. *Denotes differences between CT and CMS; #Denotes differences between CMS+VEH and CMS+FLX. Abbreviations: CT, Control; CMS, unpredictable chronic mild stress; NSF, Novelty Suppressed Feeding test; SDT, Sweet Drive test. Data presented as mean ± SEM. FLX, fluoxetine; N, Nadir; Z, Zenith. */#p < 0.05; **/##p < 0.01; ***/###p < 0.001.